Smart-Money SignalNeutral · 50/100— Insiders are net sellers over 90 days (-$60K, 5 sales vs 2 buys)
Revenue$11.9M
Net Income-$18.2M
EPS$-0.40
Market Cap$293.6M
Price Performance
Historical data including institutional events
Company Profile
J
James Mullen
CEO & Executive Director
Editas Medicine, Inc.,, is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.
